SEARCH

SEARCH BY CITATION

References

  • 1
    Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001; 357: 18511853.
  • 2
    Martinez-Mir I, Ferrer JM, Palop V, Estan L, Rubio E, Morales-Olivas FJ. Are the adverse drug reactions of amoxycillin and amoxycillin-clavulanic acid similar? Pharmacoepidemiol Drug Saf 1996; 5: 247254.
  • 3
    van den Broek JW, Buennemeyer BL, Stricker BH. Cholestatic hepatitis caused by a combination of amoxicillin and clavulanic acid (Augmentin). Ned Tijdschr Geneeskd 1988; 132: 14951497.
  • 4
    Reddy KR, Brillant P, Schiff ER. Amoxicillin-clavulanate potassium-associated cholestasis. Gastroenterology 1989; 96: 11351141.
  • 5
    Larrey D, Vial T, Pauwels A, Castot A, Biour M, David M, et al. Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut 1992; 33: 368371.
  • 6
    Hautekeete ML, Horsmans Y, Van Waeyenberge C, Demanet C, Henrion J, Verbist L, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999; 117: 11811186.
  • 7
    O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, et al. Co-amoxiclav jaundice: Clinical and histological features and HLA class II association. Gut 2000; 47: 717720.
  • 8
    Goossens H, Ferech M, Vander Stichele R, Elseviers M, ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet 2005; 365: 579587.
  • 9
    Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512521.
  • 10
    Thomson JA, Fairley CK, Ugoni AM, Forbes AB, Purcell PM, Desmond PV, et al. Risk factors for the development of amoxycillin-clavulanic acid associated jaundice. Med J Aust 1995; 162: 638640.
  • 11
    de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: A population based case-control study. Br J Clin Pharmacol 2004; 58: 7180.
  • 12
    Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996; 156: 13271332.
  • 13
    O'Brien CS, Despott EJ, Hussaini SH, Dalton HR. A high incidence of drug-induced community jaundice in the UK: Flucloxacillin and co-amoxiclav are the main culprits [Abstract]. J Hepatol 2005; 44(Suppl 4): P23.
  • 14
    Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects—review of the literature. Eur J Med Res 2001; 6: 139149.
  • 15
    Ryley NG, Fleming KA, Chapman RW. Focal destructive cholangiopathy associated with amoxycillin/clavulanic acid (Augmentin). J Hepatol 1995; 23: 278282.
  • 16
    Richardet JP, Mallat A, Zafrani ES, Blazquez M, Bognel JC, Campillo B. Prolonged cholestasis with ductopenia after administration of amoxicillin/clavulanic acid. Dig Dis Sci 1999; 44: 19972000.
  • 17
    Andrade RJ, Lucena MI, Fernandez MC, Vega JL, Camargo R. Hepatotoxicity in patients with cirrhosis, an often unrecognized problem: Lessons from a fatal case related to amoxicillin/clavulanic acid. Dig Dis Sci 2001; 46: 14161419.
  • 18
    Jordan T, Gonzalez M, Casado M, Suarez JF, Pulido F, Guerrero E, et al. Amoxicillin-clavulanic acid induced hepatotoxicity with progression to cirrhosis. Gastroenterol Hepatol 2002; 25: 240243.
  • 19
    Benichou C. Report of an international consensus meeting. Criteria of drug-induced liver disorders. J Hepatol 1990; 11: 272276.
  • 20
    Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. HEPATOLOGY 2001; 33: 123130.
  • 21
    Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4: 489499.
  • 22
    Andrade RJ, Lucena MI, Alonso A, Garcia-Cortes M, Garcia-Ruiz E, Benitez R, et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. HEPATOLOGY 2004; 39: 16031612.
  • 23
    Lucena MI, Andrade RJ, Rodrigo L, Salmeron J, Alvarez A, Lopez-Garrido MJ, et al. Trovafloxacin-induced acute hepatitis. Clin Infect Dis 2000; 30: 400401.
  • 24
    Perez Moreno JM, Saldana Gonzalez FJ, Puertas Montenegro M, Baez Perea J. Cholestatic hepatitis caused by midecamycin. Gastroenterol Hepatol 1996; 19: 459461.
  • 25
    Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: Analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. HEPATOLOGY 1995; 22: 820827.
  • 26
    Horsmans Y, Geubel AP. Amoxycillin-calvulanic acid-erythromycin cross-liver toxicity: A case report. J Hepatol 1994; 21: 911912.
  • 27
    Peire MA, Lucena MI, Ruiz-Extremera A, Jara P, Romero-Gonzalez J, Andrade RJ. Toxicidad hepatica por fármacos. Donde estamos y hacia donde caminamos. An Esp Pediatr 2002; 56: 434442.
  • 28
    Australian Adverse Drug Reactions Advisory Committee. Drug-induced liver disease: Antibiotics of continuing concern. Australian Adverse Drug Reactions Bulletin 1996; 15: 14.